Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists

Abstract Background Anti‐obesity medications (AOMs) have historically had limited weight‐loss efficacy. However, newer glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA)–based therapies seem to be more effective, including dual agonists of GLP‐1R and the glucagon receptor (GCGR) or glucose‐dependen...

תיאור מלא

מידע ביבליוגרפי
Main Authors: W. Timothy Garvey, Cathy D. Mahle, Trevor Bell, Robert F. Kushner
פורמט: Article
שפה:English
יצא לאור: Wiley 2024-06-01
סדרה:Obesity Science & Practice
נושאים:
גישה מקוונת:https://doi.org/10.1002/osp4.756